Camurus AB
Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases. The company leverages its proprietary FluidCrystal® technology and extensive R&D expertise to create new medicinal products with best-in-class potential. Camurus has products on the market for opioid dependence and a clinical pipeline including treatments for pain, cancer, and endocrine diseases. With over 250 employees and headquarters in Lund, Sweden, the company operates regional offices in the UK, Germany, Australia, and the US. Camurus aims to improve treatment outcomes, quality of life, and long-term recovery for patients, while also focusing on sustainability and responsible business practices.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Marketed long-acting treatment for opioid dependence
A marketed long-acting medicinal product for the treatment of opioid dependence based on a long-acting formulation platform.
Pipeline of long-acting product candidates
Clinical and preclinical candidates developed using long-acting formulation technology targeting pain, oncology, endocrinology and other severe or chronic diseases.
Marketed long-acting treatment for opioid dependence
A marketed long-acting medicinal product for the treatment of opioid dependence based on a long-acting formulation platform.
Pipeline of long-acting product candidates
Clinical and preclinical candidates developed using long-acting formulation technology targeting pain, oncology, endocrinology and other severe or chronic diseases.
Services
Collaborative development, licensing and alliance management to co-develop and commercialize long-acting medicines with pharmaceutical partners.
Regional commercialization capability to launch and manage products across Europe, Australia and the US, including market access and distribution activities.
Joint preclinical and clinical development programs including formulation development, preclinical testing, clinical trial execution and regulatory filings.
Collaborative development, licensing and alliance management to co-develop and commercialize long-acting medicines with pharmaceutical partners.
Regional commercialization capability to launch and manage products across Europe, Australia and the US, including market access and distribution activities.
Joint preclinical and clinical development programs including formulation development, preclinical testing, clinical trial execution and regulatory filings.
Expertise Areas
- Long-acting drug delivery
- Formulation science and CMC
- Clinical development and pharmacovigilance
- Regulatory strategy and global filings
Key Technologies
- Lipid-based liquid crystalline formulation platforms
- Long-acting parenteral depot systems
- Formulation optimization (drug loading and release kinetics)
- In vivo pharmacokinetic and release studies
News & Updates
Camurus will participate in this conference in Boston, MA, US, 16-19 June, 2025.
Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Frankfurt, 26 June.
Camurus and Lilly announced a collaboration and license agreement for long-acting FluidCrystal® incretins.
The Board of Directors of Camurus has exercised authorization for repurchase of shares to secure commitments under the Performance Share Plan 2025/2028.
Camurus announced an exercise in its employee stock options program for 2022/2026.
Camurus will participate in this conference in Boston, MA, US, 16-19 June, 2025.
Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Frankfurt, 26 June.
Camurus and Lilly announced a collaboration and license agreement for long-acting FluidCrystal® incretins.
The Board of Directors of Camurus has exercised authorization for repurchase of shares to secure commitments under the Performance Share Plan 2025/2028.
Camurus announced an exercise in its employee stock options program for 2022/2026.